Dr. Mark Gilbert on Genetics as a Predictive Tool for Treatment Response in Brain Cancer
Mark Gilbert, MD, neuro-oncologist, chief of neuro-oncology, National Institute of Health, discusses predicting how a patient's brain tumor might act and respond to treatment based on their genetics.
Mark Gilbert, MD, neuro-oncologist, chief of neuro-oncology, National Institute of Health, discusses predicting how a patient's brain tumor might act and respond to treatment based on their genetics. Gilbert says one way an oncologist might be able to predict these factors is looking at a patient's nucleotides in their DNA. He says these polymorphisms can reveal different types of enzyme activity, which in turn can potentially allow oncologists to guess more accurately at how a treatment might impact a patient.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
